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INTRODUCTION
Hirschsprung disease (HSCR, OMIM 142623), 
the most common neurocristopathy in humans (1:5000 
newborns), is characterized by the absence of enteric 
ganglia along variable lengths of the distal gastrointestinal 
tract, resulting in severe intestinal dysfunction [1]. Based on 
the length of the aganglionic region, HSCR phenotypes are 
classified as: short-segment forms (S-HSCR) which include 
patients with aganglionosis as far as the splenic flexure, 
long-segment forms (L-HSCR) in which aganglionosis 
extends beyond the splenic flexure and total colonic 
aganglionosis forms (TCA) [2]. Such aganglionosis is 
attributed to a failure of the proliferation, migration, 
differentiation and/or survival of the enteric precursors cells 
(EPCs) derived from NCCs during embryonic development 
of Enteric Nervous System (ENS). 
The ENS formation is a complex process that 
requires a specific gene expression pattern at each stage, 
and alterations throughout such pattern can lead to 
drastic consequences, as evidenced by the aganglionosis 
observed in HSCR [3]. There are several mechanisms that 
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ABSTRACT
Hirschsprung disease (HSCR, OMIM 142623) is a pathology that shows a lack 
of enteric ganglia along of the distal gastrointestinal tract. This aganglionosis is 
attributed to an abnormal proliferation, migration, differentiation and/or survival 
of enteric precursor cells (EPCs) derived from neural crest cells (NCCs) during the 
enteric nervous system (ENS) embryogenesis. DNMT3b de novo methyltransferase 
is associated with NCCs development and has been shown to be implicated in ENS 
formation as well as in HSCR. In this study we have aimed to elucidate the specific 
mechanism underlying the DNMT3b role in such processes.  We have performed the 
knockdown of Dnmt3b expression (Dnmt3b-KD) in enteric precursor cells (EPCs) to 
clarify its role on these cells in vitro. Moreover, we have analyzed several signaling 
pathways to determine the mechanisms responsible for the effect caused by Dnmt3b-
KD in EPCs. Our results seem to support that Dnmt3b-KD promotes an increase EPCs 
proliferation that may be mediated by P53 and P21 activity, since both proteins were 
observed to be down-regulated in our Dnmt3b-KD cultures. Moreover, we observed 
a down-regulation of P53 and P21 in HSCR patients. These results lead us to propose 
that DNMT3b could be involved in HSCR through P53 and P21 activity. 
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regulate gene expression during the embryogenesis of 
ENS. Among them, epigenetic mechanisms are acquiring 
increasing evidence to play a major role in the onset of this 
disease [4]. One well characterized epigenetic mechanism 
regulating gene expression is DNA methylation, which in 
mammalian is mediated by three DNA methyltransferases: 
DNMT1, DNMT3a and DNMT3b [5]. DNMT1 is the 
most abundant DNA methyltransferase in mammal 
cells, and is responsible for the maintenance of DNA 
methylation. DNMT3a and DNMT3b function as de 
novo methyltransferases and together are responsible for 
methylation pattern acquisition during gametogenesis, 
embryogenesis, and somatic tissue development as well 
as for maintaining the silence of transposable elements and 
enhancing the stability of genome. [6, 7]
DNMT3a and DNMT3b have been shown to be 
essential for the normal NCCs development in mammals 
and both of them play important roles in diseases related 
to this process [8–12]. Neural crest malformation can 
lead to craniofacial defects like cleft lip palate, heart 
septation defects and aganglionosis of the colon [13–15]. 
Specifically the Dnmt3b knockout mouse embryo shows 
rostral neural tube defects and growth impairment [8]. In 
human embryonic stem cells, knockdown of DNMT3b 
accelerates neural crest differentiation and increases the 
expression of neural crest specifier genes (PAX3, PAX7, 
FOX3, SOX10 and SNAIL2) [12]. Moreover, DNMT3b 
shows a decrease of expression in enteric precursors cells 
(EPCs) from HSCR patients compared with controls, and 
this result translates into a lower level of DNA methylation 
in HSCR patients [16].
Although it has been demonstrated the implication 
of DNMT3b in the ENS formation as well as in HSCR, 
its role in this process is unknown. Therefore, we have 
performed the study of the Dnmt3b-KD in mouse EPCs 
that were grown as Neurosphere like-bodies (NLBs). 
In these NLBs cultures we have evaluated the effect 
of Dnmt3b-KD on cell proliferation, differentiation 
and survival. In addition, we have analyzed several 
signaling pathways to determine the possible mechanisms 
responsible for the effect caused by Dnmt3b-KD in EPCs. 
RESULTS
Dnmt3b-KD in EPCs resulted in an increase of 
proliferation and/or survival
First we evaluated the expression of Dnmt3b in 
the NLBs cultures by SYBR green real-time RT-PCR 
technique. We could observe that this gene is expressed 
in EPCs from NLBs cultures (Supplementary Table 1). 
The Dnmt3b-shRNA that produced higher reduction in 
the gene expression level was Dnmt3b-shRNA1 (KD) 
(Supplementary Figure 1). Then, we analyzed the possible 
effect of Dnmt3b-KD in the NLBs cultures and observed 
a significant increase of NLBs number in KD compared 
with the control (C) and shRNA Non-Target Control 
(Non-Target) conditions (Figure 1A). We also detected an 
increase in NLBs size in the KD group compared with C 
and Non-Target groups. However Non-Target showed a 
decrease of NLBs size in comparison with the C group 
(Figure 1B). Figure 1C shows representative images of 
NLBS cultures under the three different conditions. 
Dnmt3b-KD effect on EPCs phenotypes
Evaluation of the Dnmt3b-KD effect on the 
neurogenesis was performed by flow cytometry in the 
NLBs cultures. With this purpose we analyzed the p75, 
Nestin and βlll-Tubulin markers, and observed that Non-
Target and KD cultures showed a decrease of Nestin+ 
(15% and 3% respectively) and βlll-Tubulin+ cells (6% 
and 3% respectively) compared to C culture. On the other 
hand, p75 expression level was not different among the 
groups (Figure 2). The decrease detected in the number of 
Nestin + and βlll-Tubulin+ cells was due to the treatment 
with shRNA and we observed that the Dnmt3b-KD 
seems to counteract this effect resulting in an increase 
of these cell types in KD compared with Non-Target 
cultures. We also analyzed the double positive cells for 
the studied markers. Nestin+/p75+, βlll-Tubulin+/p75 
and Nestin/βlll-Tubulin+ combinations were analyzed 
(Supplementary Figure 2). It is worthy to note that there 
were no statictically significant changes in cell phenotypes 
within the Dnmt3b-KD cultures.
Identification of the mechanisms implicated in 
cell proliferation and/or survival regulated by 
DNMT3b in EPCs
Dnmt3b-KD effect on the MAPK/ERK, PI3K/AKT 
and STAT3 pathways activation
The observation of the increase in the NLBs 
number and size in Dnmt3b-KD cultures, prompted us to 
investigate the signaling pathways that may be involved 
in this effect. For this purpose we studied MAPK/ERK, 
PI3K/AKT and STAT3 activation. All these pathways 
have been related to cell proliferation and survival. We 
analyzed the pathways activation at 24 h and observed that 
MAPK/ERK pathway in KD cultures was more activated 
than in the C and Non-Target groups (Figure 3A). On 
the other hand, both PI3K/AKT and STAT3 activations 
were subtly lower in KD and Non-Target than in the C 
cultures. At 7 days in vitro (7 div.) we observed that all 
pathways showed the same level of activation in all the 
culture conditions (Figure 3B). In summary, we detected 
weak modifications in the activation of these pathways in 
Dnmt3b-KD compared with C cultures. Therefore these 
signaling pathways do not seem related to the effect on 
EPCs proliferation and/or survival that the Dnmt3b-KD 
cultures showed.
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Dnmt3b-KD effect on Bcl-xL and p53 expression
Bcl-xL and p53 expression levels were also 
analyzed given that both proteins have been widely 
associated with cell survival. In the case of BcL-xL, no 
significant changes in its expression level were identified 
when we compared all the culture conditions (Figure 4A 
and 4B). In contrast, p53 at 24 h and 7 div. showed a 
decrease in its expression level in KD compared with the 
C and Non-Target cultures, being this difference more 
pronounced at 24 h of infection (Figure 4C). Figure 4D 
corresponds to a representative immunoblot assay image 
showing the decrease of P53 in Dnmt3b-KD cultures. 
Based in this result, we analyzed the P53 expression 
level in EPCs from HSCR patients compared to controls. 
We observed that the EPCs from HSCR patients with 
a DNMT3b low expression have a significant decrease 
in the P53 expression (30.3%) compared to controls, 
Figure 4E. 
DNMT3b seems to regulate the cell cycle through the 
P53/P21 activity
Our results suggested that the increase in the cell 
growth observed in Dnmt3b-KD cultures is mediated by 
p53 down-regulation. This prompted us to evaluate the 
expression level at 24 h and 7 div. of a group of genes 
related with P53 that participate in pathways either 
implicated in proliferation (cyclin-dependent kinase 
inhibitor p21) or in apoptosis (Bax, Puma, Casp6 and 
Casp8). We also wanted to know if the inhibitor of p53 
expression, Mdm2, was responsible of the p53 down-
Figure 1: Effect of the Dnmt3b-KD on the NLBs cultures. (A) Effect of Dnmt3b-KD in the number of NLBs (p value KD/C = 0.0004, 
KD/Non-Target = 0.02). (B) Effect of Dnmt3b-KD in the size of NLBs. (C) Representative image showing the appearance of each one of 
the three different culture conditions (p value KD/C = 0.02, KD/Non-Target = 0.03).  Scale bar 200 µm. Data are represented as mean ± 
SEM.
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regulation observed in Dnmt3b-KD. As a result, we just 
observed a decrease in the expression level of p21 (17%) 
at 24 h (Figure 5A), while at 7 div., no significant changes 
were detected in any of the analyzed genes (Figure 5B). 
Therefore, we decided to analyze the expression level 
of P21 in EPCs from those HSCR patients with a low 
expression of DNMT3b in comparison with that of 
controls, and observed a P21 down-regulation (27 %) in 
EPCs from HSCR patients (Figure 5C).
DISCUSSION
In this work we have studied Dnmt3b-KD in mouse 
EPCs cultures in order to further investigate the role of 
this methyltranferase on EPCs, given its significant down-
regulation observed in HSCR patients [16].
We noticed a significant increase of NLBs number 
and size, which suggests the possible regulatory role of 
Dnmt3b in the proliferation and/or survival on EPCs. 
In this sense, DNMT3b has been widely related with 
these cellular processes and specifically its depletion in 
different human cells has shown to produce extremely 
variable effects [17–19]. There are many studies that 
have demonstrated that a reduction of DNMT3b protein 
levels induces antiproliferative effects in human cancer 
cells which were attributed to the demethylation and 
reactivation of tumor suppressor genes. Therefore, de 
novo methyltransferase DNMT3b is implicated in the 
establishment of gene-specific hypermethylation during 
cancer development and progression [17–20]. Recently, it 
has been also described such DNMT3b antiproliferative 
effect on vascular smooth muscle cells from human [21]. 
Conversely, Umehara et al. showed that DNMT3b induces 
the initiation of stem/progenitor cell differentiation via 
down-regulation of embryonic stem cell proliferation 
coordinated with the down-regulation of Oct3/4 and 
Nanog genes [22]. Therefore, this study suggests that 
DNMT3b plays an important role in the initial process 
of stem cell differentiation and in the inhibition of their 
proliferation. Such role of DNMT3b is in accordance with 
the results obtained in Dnmt3b-KD NLBs cultures, where 
the DNMT3b depletion showed an increase of the EPCs 
proliferation and/or survival.
On the other hand, cell differentiation status is defined 
by the gene expression profile, which is coordinately 
controlled by epigenetic mechanisms. There are in vivo 
and in vitro studies that suggest that DNMT3b is required 
for the initial steps of progenitor cell differentiation, and 
DNMT3a is required for maturation processes of cell 
differentiation [23, 24]. In our case, the EPCs phenotypes 
in Dnmt3b-KD cultures did not show significant changes 
when they were compared with the C condition. A decrease 
in the percentage of Nestin+ (p75+ or  βlll-Tubulin+) and 
βlll-Tubulin+ (p75+ or  Nestin+) cells was noticed, though 
in Non-Target cultures the decrease was more pronounced. 
Therefore, we did not observe that Dnmt3b-KD triggered 
a loss of differentiation capacity in our NLBs culture, in 
contrast with which has been previously described [23–25].
Taking to account our whole results, we propose 
that DNMT3b could have an antiproliferative effect on 
EPCs and it does not affect their neurogenic capacity. In 
order to know the mechanisms by which DNMT3b act on 
Figure 2: Effect of the Dnmt3b-KD on the cell phenotypes derived from NLBs. Effects of Dnmt3b-KD on the EPCs that 
express Nestin (Nest), β-III tubulin (β-III), or p75 markers in the different culture conditions. Data are represented as mean ± SEM.
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EPCs proliferation and/or survival, we studied MAPK/
ERK, PI3K/AKT and STAT3 pathways activation in 
the NLBs cultures. We selected such pathways because 
it has been shown that RET the main protein implicated 
in the onset of HSCR [26] can activate them [27–29]. 
In addition such pathways have a role on proliferation, 
survival, apoptosis, migration, and differentiation of EPCs 
and they are most likely to be affected by HSCR-related 
changes [30]. We did not observe significant changes in 
these signaling pathways in KD in comparison with C 
cultures. However, when we analyzed the p53 and Bcl-
xL expression, both proteins implicated in the apoptosis 
and/or cell cycle regulation, we observed that p53 showed 
a significant lower expression maintained in time in KD 
cultures and Bcl-xL did not show significant changes. 
We noticed that this decrease of p53 expression does not 
seem to be regulated by MDM2 in EPCs from mouse in 
response to the DNMT3b lower expression. Based on these 
results, we evaluated the expression level of P53 in EPCs 
from HSCR patients that had previously shown a decline 
in DNMT3b expression [16], and a P53 down-regulation 
was also detected. P53 is a well-known protein involved 
in the induction of apoptosis [31, 32]. Recently, it has 
been published the relationship of P53 with the NCCs 
development and with the onset of neurocristopathies 
in zebrafish [33]. On the other hand P53 also has been 
related with DNMT3b, since it has been identified that 
the hypermethylation of p53 promoter by DNMT3b 
causes a decrease of its expression level and promotes an 
increase of cell proliferation [21]. In concordance with 
this effect on cell growth, the decrease observed in p53 
expression level in our EPCS (KD-Dnmt3b and HSCR 
patients) correlated with the p21 down-regulation. The 
cyclin-dependent kinase inhibitor p21 is a P53 target gene 
known to play a key role in P53-mediated cell cycle arrest 
[34, 35]. Postnatal P53-deficient mice exhibit increased 
proliferation within the Subventricular Zone and increased 
neurogenesis [36]. Furthermore, the neural precursor cells 
derived from P53-null mice exhibit reduced apoptosis and 
enhanced proliferation [37]. Taking into account all of 
these correlations, we propose a possible antiproliferative 
effect for DNMT3b through P53/P21 activity.  
Figure 3: Effect of the Dnmt3b-KD on the cell signaling pathways activation in NLBs cultures. (A and B) Graphs showing 
the effect of Dnmt3b-KD in the different culture conditions on the activation of MAPK/ERK (MAPK), PI3K/AKT (AKT) and STAT3 
pathways at 24 h and 7 div respectively. Data are represented as mean ± SEM.
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Figure 4: Effect of the Dnmt3b-KD on the expression of Bcl-xL and p53 in NLBs cultures. (A) Effect of Dnmt3b-KD on 
the Bcl-xL expression in the three different conditions cultures at 24 h and 7 div. (B) Representative image showing the effect observed in 
the Bcl-xL expression level in the three different conditions at 24 h and 7 div. (C) Effect of Dnmt3b-KD on the p53 expression in the three 
different conditions cultures at 24 h and 7 div. (p value KD/C 24 h = 0.0006, KD/C 7 div. = 0.028). (D) Representative image showing 
the effect observed in the p53 expression level in the three different conditions at 24 h and 7 div. Actin was used as a loading control. 
(E) Graph showing the difference between P53 expression levels in EPCs from HSCR patients with DNMT3b low expression and in EPCs 
from controls (p value = 0.0003). Data are represented as mean ± SEM.
Oncotarget106449www.impactjournals.com/oncotarget
Nervous System development is a process that 
integrates cell proliferation, cell differentiation cell 
cycle arrest and programmed cell death. Apoptosis 
is a conserved mechanism as well as a fundamental 
developmental process by which the final cell number 
in the nervous system is established [38]. It is worthy to 
note that Bordeaux et al. described a pro-apoptotic role of 
RET in ENS development by inducing cell death in the 
NCCs that migrate to areas beyond ligands availability 
[39]. In addition it has been described that cell cycle arrest 
plays an important role in the establishment of the critical 
cell population for the correct formation of the Nervous 
System [40]. Therefore cell death and cell cycle arrest 
seem to be important processes required during early 
development of the ENS. This reinforces the idea that 
control of NCCs number in the developing gut is critical 
for normal ENS formation [41]. In this sense, our results 
would correlate with the role that the cell cycle arrest plays 
in NCCs development, and this regulation apparently 
seems to occur through P53 and P21 activity.
In conclusion, this study suggests that DNMT3b 
has an antiproliferative effect on mouse EPCs that 
could to be mediated through the P53 and P21 activity. 
This proposed mechanism is supported by the observed 
correlation between the down-regulation of P53 and P21 
in EPCs from HSCR patients that had previously shown 
a lower expression of DNMT3b. Therefore, DNMT3b 
down-regulation is concomitant with a decrease in the P53 
and P21 expression levels and with an increase of EPCs 
proliferation, concluding that all these events together 
might contribute to an anomalous formation of the ENS 
and, ultimately, to the onset of HSCR.
Figure 5: Effect of the Dnmt3b-KD on P53-pathways related genes in NLBs cultures. (A and B) Graph showing the expression 
levels of Mdm2, p21, Casp6, Casp8, Bax and Puma in Dnmt3b-KD EPCs cultures at 24 h and 7 div.  A significant decrease of expression 
of p21 was detected at 24 h (p value KD/C = 0.002, KD/Non-Target = 0.001). (C) Graph showing the difference between P21 expression 




Gut samples from mice and human
Gut tissue was obtained from CD1 mice (P7) and 
from human postnatal tissues of ganglionic gut from 
3 sporadic non-related patients diagnosed of S-HSCR 
(male: female = 1:2), as well as from 4 patients with 
other gastrointestinal disorders (anorectal malformations 
and enterocolitis) undergoing gut resection surgery at our 
Hospital that were used as controls (male: female = 2:2). 
For both HSCR patients and control individuals, age 
ranged from 3 months to 3 years. All procedures involving 
mice were performed in accordance with the Guidelines 
of the European Union Council (86/609/EU) and Spanish 
regulations (BOE 67/8509-12) for the use of laboratory 
animals. The written informed consent for surgery, clinical 
and molecular genetic studies was obtained from all the 
human participants or their guardians. The study was 
approved by the Ethics Committee for clinical research of 
the University Hospital Virgen del Rocío (Seville, Spain) 
and complies with the tenets of the declaration of Helsinki. 
Culture of enteric precursors cells as NLBs
Gut samples were cut into pieces of 1 mm2 and 
incubated in a solution of 0,26 mg/mL Trypsin Collagenase, 
5 mg/mL Dispase, 0,28 mg/mL Hyaluroniodase, 3,3 u/mL 
Elastase and 0,6 mg/mL Collagenase in phosphate-buffered 
saline (PBS) for up to 30 minutes at 37°C. Digested tissue 
was triturated and washed, and the cells were cultured 
in the following conditions: Dulbecco’s modified Eagle 
medium (DMEM; 1 mg/mL Glucose) containing 100 U/mL 
penicillin, 100 g/mL streptomycin, supplemented with 2 mM 
L-glutamine (Gibco, Life Technology, California, USA), 
0.05 mM 2-mercaptoethanol, 1% (v/v) N1 (Sigma Aldrich, 
Poole, Dorset, UK), 10% (v/v) Human serum, 20 ng/mL basic 
fibroblast growth factor (bFGF), 20 ng/mL epidermal growth 
factor (EGF) and 10 ng/mL glial cell derived neurotrophic 
factor (GDNF) (Peprotech, London, UK).  Finally, after 4–7 
days in vitro (div) the NLBs were formed.
Gene expression study by quantitative real-time 
PCR (qRT-PCR) 
Purification and synthesis of cDNA from mouse 
NLBs were performed using the protocol provided 
by µMACS mRNA isolation Kit and µMACS cDNA 
Synthesis Kit in a thermo MAKSTM Separator (MACS 
Miltenyi Biotech, Germany) or RNAeasy Micro kit and 
RT2 First Strand kit (Qiagen, Germany). Expression 
studies were carried out in an Applied Biosystems 7900HT 
system (Life Technologies, USA) through SYBR Green 
method (Bio-Rad, USA). Analysis was performed using 
the RQ Manager Software (Life Technologies, USA). 
Beta-Actin or Gapdh were used as endogenous controls. 
To determine mRNA levels specific primer pairs for 
Dnmt3b, P53, p21, P21, Bax, Puma, Casp6, Casp8 and 
Mdm2 (Supplementary Table 2) were used. Following the 
software recommendations, the upper limit of the cycle 
threshold (Ct) was set to be 35. Therefore we considered 
positive expression exclusively when Ct values <35.
Dnmt3b shRNA-Expressing Lentiviral Vector 
and infection of the EPCs 
We knocked down the Dnmt3b expression in mouse 
NLBs cultures using lentiviral transduction. We used 
constructs that constitutively expressed a small hairpin RNA 
(shRNA) directed against Dnmt3b mRNA. As a negative 
control we employed a shRNA Non-Target Control. 
Several Dnmt3b shRNA-expressing lentiviral vectors were 
tested (Sigma Aldrich, USA): Dnmt3b-shRNA1, Dnmt3b-
shRNA2, Dnmt3b-shRNA3 and Dnmt3b-shRNA4 and the 
multiplicity of infection (MOI) used was 1,5. Dnmt3b-
shRNA1 was observed to produce a higher reduction in the 
gene expression level of Dnmt3b (Supplementary Figure 1). 
Therefore, we selected this construction to continue with 
the approach. The cultures of enteric precursors extracted 
from mouse gut were divided into 3 groups: uninfected 
group (C), shRNA Non-Target Control group (Non-Target), 
and Dnmt3b-shRNA1 group (KD). The cultures of single 
enteric precursors were infected with the shRNAs (KD or 
Non-Target) and they were maintained during 7 div. in order 
to obtain NLBs suitable to detect changes in the processes 
of interest. 
Cell proliferation assays
Enteric precursor cells isolated from mouse gut 
were grown at a density of 2 × 105 cells/well during 7 div. 
The number of NLBs/well generated was counted under 
phase microscopy (IX71, Olympus, Japan) 7 div. later. 
To measure the NLBs size, images of twenty fields per 
well were obtained, and the surface of the formed NLBs 
(at least 60 NLBs per condition) was estimated using the 
Microimage analysis system software (Olympus, Japan).
Flow cytometry
The NLBs obtained from the different conditions of 
culture were enzymatically and mechanically dissociated to 
obtain a single-cell suspension in which we carried out the 
cell labeling. The cells were fixed with 4% (weight/volume) 
paraformaldehyde in 0.1 mol/l phosphate-buffered saline. 
Then, they were incubated for 1 hour in 2.5% (weight/
volume) bovine serum albumin in phosphate-buffered 
saline and with primary (16 hours at 4°C) and secondary 
antibodies (1 hour at room temperature). Several primary 
antibodies were used: anti-Nestin (goat polyclonal; 1:1000) 
(Santa Cruz Biotechnology, Inc) as a neural precursor cells 
marker, anti-β III Tubulin (mouse monoclonal; 1:500) as a 
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neuronal precursor cells marker (Merck Millipore, German) 
and anti-p75 (rabbit polyclonal; 1:500) as a enteric precursor 
cells marker (Abcam, UK). The secondary antibodies were 
anti-goat IgG labeled with Cy5, anti-mouse Ig G labeled 
with Cy2 (1:200; Jackson Immuno Research Laboratories 
Inc, UK), and anti-rabbit IgG labeled with Alexa Fluor 
568 (1:200; Life Technologies, USA) respectively. Flow 
cytometry analysis data were collected using the LRS 
II Fortessa cell analyzer (Becton Dickinson, USA). The 
expressions of Nestin, βIII-Tubulin and p75 markers as well 
as of different combinations of these markers were analyzed 
in the EPCs.
Immunoblot assays
Uninfected, KD and Non-Target NLBs were 
lysed at 24 h and 7 div. with RIPA Buffer that contained 
protease and phosphatase inhibitors (Roche, Germany). 
Supernatants were collected by centrifugation (16000 g) 
and their protein concentration was measured by the 
Bradford-based Bio-Rad microassay method. Equal 
amounts of total protein from each cellular extract 
(20 mg) were separated by SDS-PAGE and transferred 
onto a polyvinylidene difluoride membrane. The 
immunodetection was carried out using the following 
rabbit polyclonal primary antibodies against the following 
proteins: extracellular signal-regulated kinase (Erk1/2) 
(1:1000), pp-Erk (p44/42, Thr202/Tyr204) (1:1000), 
p-Akt (Ser437) (1:1000), Akt (1:1000), p-Stat3 (Tyr705) 
(1:1000) and Stat3 (1:1000) for the study of the activation 
of cell signaling pathways, and p53 (1:1000) and Bcl-xL 
(1:2000) for the study of cell apoptosis (Cell Signaling 
Technology, USA). After washing with T-TBS (Tris-
buffered salt solution with Tween), the membrane was 
incubated with the anti-rabbit IgG HRP-linked secondary 
antibody (1:2000) (Cell Signaling Technology). Bands 
were made visible by ChemiDoc XRS (Bio-Rad, USA). 
Quantification was done by photodensitometry with the 
Image Lab. 3.0 software (Bio-Rad, USA). 
Statistical analysis
Data are presented as the mean ± SEM (Standard 
Error Mean) of values obtained from at least three assays. 
Comparisons between values obtained in the C, KD, and 
Non-Target conditions were analyzed using the Student´s 
t-test. Differences were considered significant when 
p value < 0.05. 
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